Diabetes drug shows promise for healing hearts after attack

NCT ID NCT07169981

Completed Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at whether the diabetes drug empagliflozin (Jardiance) can help repair heart damage in diabetic patients who had a major heart attack. 200 participants took either 10 mg or 25 mg of the drug daily for 6 months. Researchers measured changes in heart size, pumping strength, and overall function to see if the drug improves heart remodeling.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: empagliflozin (Jardiance)
What this could lead to: If successful, this could show that empagliflozin helps repair heart damage after a heart attack in diabetic patients, potentially improving heart function and reducing future heart problems.
What could go wrong: This is a small, completed Phase 2 trial, so results are preliminary. The benefits seen may not be large or may not apply to all patients. The drug is already approved for diabetes and heart failure, so major new risks are unlikely, but side effects like dehydration or urinary infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTERIOR ST-ELEVATION MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus heart failure ST-elevation myocardial infarction systolic heart failure type 2 diabetes mellitus Ventricular Remodeling

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETE MELLITUS HEART FAILURE REMODELING, LEFT VENTRICLE

Contacts and locations

Locations

Ain Shams University Hospitals

Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.